ClinicalTrials.gg
TerminatedNCT02847650Updated Nov 23, 2020Results posted

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

A Phase 2 interventional study of Placebo and PF-06649751 in Parkinson Disease, sponsored by Pfizer. Terminated at 37 sites in 4 countries. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-23.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Why this study was terminated
Study B7601011 was terminated on 29 Jan 2018 due to lack of efficacy in moderate/advanced Parkinson's disease.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.

Enrollment
6th of 11
57 · median 57
Started
2016
with 1 other
Phase 2
2 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
4 of 11
Pfizer

Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 6th largest by enrollment, is one of 2 that started in 2016, is one of 2 in phase 2, and was the 4th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About tavapadon

tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing tavapadon in Parkinson Disease as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.

Read the detailed description

The B7601011 study has a randomized, double-blind, placebo-controlled parallel group design. Approximately 88 subjects will be randomized to 2 treatment groups. Each subject will participate in the study for approximately 23 weeks including a 30 day screening period, 15 week double blind treatment period, and an approximately 28 day follow-up period.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Early Parkinson Disease
  • Phase 2
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females of non- and/or male subjects
  • Clinical diagnosis of Parkinson's disease.
  • Parkinson's Disease Hoehn \& Yahr Stage I-III inclusive
  • Treatment naïve or history of prior incidental treatment with dopaminergic agents for no more than 28 days
  • Able to refrain from any Parkinson's disease medication not permitted by the protocol.

Exclusion criteria

Exclusion Criteria:

  • History or presence of atypical Parkinsonian syndrome.
  • Severe acute or chronic medical or psychiatric condition or cognitive impairment or laboratory abnormality.
  • Any condition possibly affecting drug absorption.
  • Participation in other studies involving drug(s), or treatment with any investigational drug within 30 days.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
57 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    PF-06649751

    Drug: PF-06649751

Interventions

  • DrugPlacebo

    Also known as: oral tablet once daily

  • Also known as: flexible dose oral tablet once daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Total Score at Week 15

    MDS-UPDRS Part III was used to assess the motor signs of Parkinson's disease. It was comprised of 33 sub-scores based on 18 items, several with right, left or other body distribution scores. Each question was anchored with 5 responses that were linked to commonly accepted clinical terms: 0=normal, 1=slight, 2=mild, 3=moderate, and 4=severe. The MDS-UPDRS Part III total score range is 0-132. Higher score indicates more severe motor signs of Parkinson's disease. A negative change from baseline represents an improvement in motor function.

    Time frame: Baseline (Day -1/randomization), Week 15

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment.

    Time frame: From first dose of study treatment up to 28 days after last dose (up to Day 133)

  2. Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

    Following safety laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, white blood cell count, absolute total neutrophils, absolute eosinophils, absolute basophils, absolute monocytes, and absolute lymphocytes); chemistry (blood urea nitrogen/urea and creatinine, glucose , calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], total bilirubin, alkaline phosphatase, uric acid, albumin, total protein); urinalysis (pH, qualitative glucose, qualitative protein, qualitative blood, ketones, nitrites, leukocyte esterase, urine bilirubin, urobilinogen, urine creatinine, microscopy, and specific gravity).

    Time frame: Baseline (Day -1/randomization) up to Day 119 follow-up visit

  3. Number of Participants With Vital Signs Data Meeting Categorical Summarization and Orthostatic Hypotension Criteria

    Vital signs categorical summarization criteria: 1) supine and standing systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine and standing diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) standing pulse rate \<40 or \>140 bpm; 5) maximum change from baseline (increase or decrease) in supine and standing DBP greater than or equal to (\>=) 20 mmHg; 6) maximum change from baseline (increase or decrease) in supine and standing SBP \>=30 mmHg. Orthostatic hypotension criterion was defined as a decrease of \>=20 mmHg for SBP or \>=10 mmHg for DBP 2 minutes after standing from a supine position.

    Time frame: Baseline (Day -1/randomization) up to Day 119 follow-up visit

  4. Number of Participants Meeting the Categorical Summarization Criteria for Electrocardiogram (ECG) Parameters

    ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): \>=140 milliseconds (msec), \>=50% increase from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): \>=300 msec, \>=25% increase when baseline is \> 200 msec or \>=50% increase when baseline is less than or equal to (\<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of \>=500 msec; 4) QTcF interval (QT corrected for heart rate using Fridericia's formula): absolute value of 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; an increase from baseline of 30 to \<60 msec or \>=60 msec.

    Time frame: Baseline (Day -1/randomization) up to Day 119 follow-up visit

  5. Number of Participants With Worsening and New Onset Suicidality as Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS responses were mapped to the Columbia Classification Algorithm of Suicide Assessment (C-CASA). Participants with new onset suicidality were those without suicidal ideation and behavior at baseline and reported any suicidal behavior or ideation post-baseline as assessed by C-CASA code mapped from C-SSRS data. Participants with worsening suicidality were those who moved to a lower numbered C-CASA category than was reported at baseline.

    Time frame: Baseline (Day -1/randomization) up to Day 119 follow-up visit

  6. Change From Baseline in Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS) Total Score at Days 35, 63, and 105

    The QUIP-RS has 4 primary questions pertaining to commonly reported thoughts, urges/desires, and behaviors associated with impulsive-compulsive disorder , each applied to the 4 impulsive-compulsive disorders (compulsive gambling, buying, eating, and sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). Each question is anchored with the following 5 responses: Never (0), Rarely (1), Sometimes (2), Often (3), and Very Often (4). The scoring range for each item (ie, disorder) is 0-16. The QUIP-RS total score range is 0-64. Higher score indicates a greater level of the impulsive compulsive disorder.

    Time frame: Baseline (Day -1 or randomization); Days 35, 63, 105

  7. Total Physician Withdrawal Checklist (PWC-20) Score

    The PWC-20 is a 20-item reliable and sensitive instrument for the assessment of benzodiazepine-like discontinuation symptoms. The total PWC-20 score is the sum of 20 item scores and ranges between 0 and 60. The higher score indicates more frequent/severe symptoms.

    Time frame: Day 119

07

Results

Posted Jan 15, 2019
Limitations and caveats
This study was terminated early by the sponsor due to a companion study, B7601003 (NCT02687542; a dose ranging, Phase 2b study in motor fluctuators) meeting futility criteria at Interim Analysis.

Participant flow

Participant flow — Overall Study
MilestonePF-06649751Placebo
Started2928
Completed2522
Not completed46
Withdrew: Adverse event24
Withdrew: Lost to follow-up10
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryChange From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Total Score at Week 15

MDS-UPDRS Part III was used to assess the motor signs of Parkinson's disease. It was comprised of 33 sub-scores based on 18 items, several with right, left or other body distribution scores. Each question was anchored with 5 responses that were linked to commonly accepted clinical terms: 0=normal, 1=slight, 2=mild, 3=moderate, and 4=severe. The MDS-UPDRS Part III total score range is 0-132. Higher score indicates more severe motor signs of Parkinson's disease. A negative change from baseline represents an improvement in motor function.

Time frame:
Baseline (Day -1/randomization), Week 15
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Total Score at Week 15
units on a scalePF-06649751Placebo
Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Total Score at Week 15-9.0 ± 1.54-4.3 ± 1.65
Statistical analysis
  • PF-06649751 vs Placebo · Mixed Models Analysis · p = 0.0407 · Least squares mean difference: -4.8 · 90% CI -8.6 to -1.0
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment.

Time frame:
From first dose of study treatment up to 28 days after last dose (up to Day 133)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPF-06649751Placebo
AEs2518
SAEs10
SecondaryNumber of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

Following safety laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, white blood cell count, absolute total neutrophils, absolute eosinophils, absolute basophils, absolute monocytes, and absolute lymphocytes); chemistry (blood urea nitrogen/urea and creatinine, glucose , calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], total bilirubin, alkaline phosphatase, uric acid, albumin, total protein); urinalysis (pH, qualitative glucose, qualitative protein, qualitative blood, ketones, nitrites, leukocyte esterase, urine bilirubin, urobilinogen, urine creatinine, microscopy, and specific gravity).

Time frame:
Baseline (Day -1/randomization) up to Day 119 follow-up visit
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsPF-06649751Placebo
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)1919
SecondaryNumber of Participants With Vital Signs Data Meeting Categorical Summarization and Orthostatic Hypotension Criteria

Vital signs categorical summarization criteria: 1) supine and standing systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine and standing diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) standing pulse rate \<40 or \>140 bpm; 5) maximum change from baseline (increase or decrease) in supine and standing DBP greater than or equal to (\>=) 20 mmHg; 6) maximum change from baseline (increase or decrease) in supine and standing SBP \>=30 mmHg. Orthostatic hypotension criterion was defined as a decrease of \>=20 mmHg for SBP or \>=10 mmHg for DBP 2 minutes after standing from a supine position.

Time frame:
Baseline (Day -1/randomization) up to Day 119 follow-up visit
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Data Meeting Categorical Summarization and Orthostatic Hypotension Criteria
ParticipantsPF-06649751Placebo
Supine SBP <90 mmHg00
Standing SBP <90 mmHg00
Supine DBP <50 mmHg00
Standing DBP <50 mmHg00
Supine pulse rate <40 bpm00
Supine pulse rate >120 bpm00
Standing pulse rate <40 bpm00
Standing pulse rate >140 bpm00
Maximum increase in standing DBP >=20 mmHg00
Maximum increase in standing SBP >=30 mmHg00
Maximum increase in supine DBP >=20 mmHg01
Maximum increase in supine SBP >=30 mmHg03
Maximum decrease in standing DBP >=20 mmHg82
Maximum decrease in standing SBP >=30 mmHg41
Maximum decrease in supine DBP >=20 mmHg91
Maximum decrease in supine SBP >=30 mmHg50
SBP postural difference(supine-standing) >=20mmHg12
DBP postural difference(supine-standing) >=10mmHg31
SecondaryNumber of Participants Meeting the Categorical Summarization Criteria for Electrocardiogram (ECG) Parameters

ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): \>=140 milliseconds (msec), \>=50% increase from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): \>=300 msec, \>=25% increase when baseline is \> 200 msec or \>=50% increase when baseline is less than or equal to (\<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of \>=500 msec; 4) QTcF interval (QT corrected for heart rate using Fridericia's formula): absolute value of 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; an increase from baseline of 30 to \<60 msec or \>=60 msec.

Time frame:
Baseline (Day -1/randomization) up to Day 119 follow-up visit
Reported as:
Count of participants · Participants
Number of Participants Meeting the Categorical Summarization Criteria for Electrocardiogram (ECG) Parameters
ParticipantsPF-06649751Placebo
PR interval >=300 msec00
QRS duration >=140 msec00
QT interval >=500 msec00
QTcF interval >=450 msec to <480 msec00
QTcF interval >=480 msec to <500 msec00
QTcF interval >=500 msec00
Percent increase in PR interval >=25/50%00
Percent increase in QRS duration >=50%00
Increase in QTcF interval >=30 msec to <60 msec12
Increase in QTcF interval >=60 msec00
SecondaryNumber of Participants With Worsening and New Onset Suicidality as Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS responses were mapped to the Columbia Classification Algorithm of Suicide Assessment (C-CASA). Participants with new onset suicidality were those without suicidal ideation and behavior at baseline and reported any suicidal behavior or ideation post-baseline as assessed by C-CASA code mapped from C-SSRS data. Participants with worsening suicidality were those who moved to a lower numbered C-CASA category than was reported at baseline.

Time frame:
Baseline (Day -1/randomization) up to Day 119 follow-up visit
Reported as:
Count of participants · Participants
Number of Participants With Worsening and New Onset Suicidality as Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsPF-06649751Placebo
Worsening suicidality00
New onset suicidality10
SecondaryChange From Baseline in Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS) Total Score at Days 35, 63, and 105

The QUIP-RS has 4 primary questions pertaining to commonly reported thoughts, urges/desires, and behaviors associated with impulsive-compulsive disorder , each applied to the 4 impulsive-compulsive disorders (compulsive gambling, buying, eating, and sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). Each question is anchored with the following 5 responses: Never (0), Rarely (1), Sometimes (2), Often (3), and Very Often (4). The scoring range for each item (ie, disorder) is 0-16. The QUIP-RS total score range is 0-64. Higher score indicates a greater level of the impulsive compulsive disorder.

Time frame:
Baseline (Day -1 or randomization); Days 35, 63, 105
Reported as:
Mean · units on a scale
Change From Baseline in Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS) Total Score at Days 35, 63, and 105
units on a scalePF-06649751Placebo
Change from baseline at Day 350.2 ± 5.231.9 ± 9.49
Change from baseline at Day 63-1.1 ± 5.991.1 ± 9.02
Change from baseline at Day 105-1.6 ± 4.54-0.2 ± 5.38
SecondaryTotal Physician Withdrawal Checklist (PWC-20) Score

The PWC-20 is a 20-item reliable and sensitive instrument for the assessment of benzodiazepine-like discontinuation symptoms. The total PWC-20 score is the sum of 20 item scores and ranges between 0 and 60. The higher score indicates more frequent/severe symptoms.

Time frame:
Day 119
Reported as:
Median · units on a scale
Total Physician Withdrawal Checklist (PWC-20) Score
units on a scalePF-06649751Placebo
Total Physician Withdrawal Checklist (PWC-20) Score1.50 (0 to 12.00)1.00 (0 to 11.00)

Adverse events

Collected over From first dose of study treatment up to 28 days after last dose (up to Day 133). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-066497510/29 (0%)1/29 (3.4%)22/29 (75.9%)
Placebo0/28 (0%)0/28 (0%)12/28 (42.9%)
Most frequent serious events
Most frequent serious events
EventPF-06649751Placebo
Suicidal ideationPsychiatric disorders1/290/28
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPF-06649751Placebo
NauseaGastrointestinal disorders9/292/28
HeadacheNervous system disorders7/292/28
Dry mouthGastrointestinal disorders5/290/28
SomnolenceNervous system disorders4/291/28
TremorNervous system disorders4/292/28
FatigueGeneral disorders3/293/28
DiarrhoeaGastrointestinal disorders1/293/28
Decreased appetiteMetabolism and nutrition disorders3/290/28
ArthralgiaMusculoskeletal and connective tissue disorders3/290/28
Hot flushVascular disorders3/290/28

Baseline characteristics

All participants who received at least 1 dose of study treatment (PF-06649751 or placebo).

Age, Continuous
Age, Continuous(years)PF-06649751PlaceboTotal
Mean64.76 ± 8.3463.36 ± 9.1664.07 ± 8.71
Sex: Female, Male
Sex: Female, Male(Participants)PF-06649751PlaceboTotal
Female91423
Male201434
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PF-06649751PlaceboTotal
Hispanic or Latino213
Not Hispanic or Latino272754
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PF-06649751PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American134
White282553
More than one race000
Unknown or Not Reported000
08

Study locations

37 sites
  • St Joseph's Hospital and Medical Center, Barrow Neurology Clinics
    Phoenix, Arizona 85013, United States
  • St. Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
  • University of Miami
    Miami, Florida 33136, United States
  • University of South Florida Carol and Frank Morsani Center for Advanced Health Care
    Tampa, Florida 33612, United States
  • University of South Florida Faculty Office Building
    Tampa, Florida 33612, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • University of South Florida Parkinson's Disease and Movement Disorders Center
    Tampa, Florida 33613, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Asheville Neurology Specialists PA
    Asheville, North Carolina 28806, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Toledo, Gardner-McMaster Parkinson Center
    Toledo, Ohio 43614, United States
  • University of Toledo
    Toledo, Ohio 43614, United States
  • AS Clinical Research Consultants of North Texas, PLLC
    Greenville, Texas 75401, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Sentara Neurology Specialists
    Virginia Beach, Virginia 23456, United States
  • Hôpital Henri Mondor
    CRÉTEIL Cedex, 94010, France
  • Hopital Henri Mondor
    Créteil, 94010, France
  • CHU de Grenoble Alpes
    Grenoble, 38043, France
  • CHU Grenoble Alpes
    La Tronche, 38700, France
  • Hospital de La Timone
    Marseille, 13385 Cedex 05, France
  • Hospital La Timone
    Marseille, 13385 cedex 05, France
  • Hopital Pitie Salpetriere
    Paris, 75013, France
  • Hopital Pitie-Salpetriere
    Paris, 75651 cedex 13, France
  • St. Josef Hospital GmbH
    Bochum, Nordrhein-westfalen 44791, Germany
  • Praxis Oehlwein Outpatient clinic for PD, DBS, Movement Disorders
    Gera, 07551, Germany
  • Klinik Haag i. OB
    Haag I. OB, 83527, Germany
  • Paracelsus-Elena-Klinik Kassel
    Kassel, 34128, Germany
  • Universitätsklinikum Gießen und Marburg GmbH
    Marburg, 35043, Germany
  • University hospital Tuebingen
    Tuebingen, 72076, Germany
  • Universitaetsklinik Ulm
    Ulm, 89081, Germany
  • Edith Wolfson Medical Center
    Holon, 58100, Israel
  • Pharmacy, Edith Wolfson Medical Center
    Holon, 58100, Israel
09

References and documents

Publications

  • Riesenberg R, Werth J, Zhang Y, Duvvuri S, Gray D. PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial. Ther Adv Neurol Disord. 2020 Mar 6;13:1756286420911296. doi: 10.1177/1756286420911296. eCollection 2020. PubMed 32201505 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2016 to primary completion in Jan 2018, 15 months.

Results were first posted in Jan 2019, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2016
First posted
Jul 28, 2016
StartActual
Oct 17, 2016
Primary completionActual
Jan 29, 2018
CompletionActual
Jan 29, 2018
Results first posted
Jan 15, 2019
Last update
Nov 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02847650
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 28, 2016
Start date
Oct 17, 2016
Primary completion
Jan 29, 2018
Completion
Jan 29, 2018
Results posted
Jan 15, 2019
Last update
Nov 23, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion